US6835557B1
(en)
*
|
1980-01-08 |
2004-12-28 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
|
ATE25985T1
(de)
*
|
1980-06-12 |
1987-04-15 |
Japan Found Cancer |
Plasmid.
|
US6610830B1
(en)
|
1980-07-01 |
2003-08-26 |
Hoffman-La Roche Inc. |
Microbial production of mature human leukocyte interferons
|
US4810645A
(en)
*
|
1981-08-14 |
1989-03-07 |
Hoffmann-La Roche Inc. |
Microbial production of mature human leukocyte interferon K and L
|
IE54592B1
(en)
*
|
1982-03-08 |
1989-12-06 |
Genentech Inc |
Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
|
US5399684A
(en)
*
|
1982-05-20 |
1995-03-21 |
Washington Research Foundation |
DNA sequences expressing mammalian alpha-1-antitrypsin
|
DE3220116A1
(de)
*
|
1982-05-28 |
1983-12-01 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
|
JPS60222500A
(ja)
*
|
1983-12-19 |
1985-11-07 |
シエリング・コ−ポレ−シヨン |
新規ハイブリツドインタ−フエロン
|
US5248666A
(en)
*
|
1984-03-23 |
1993-09-28 |
Oncogen |
Methods for inhibiting neoplastic cell proliferation using platelet factor 4
|
US4710465A
(en)
*
|
1984-04-19 |
1987-12-01 |
Yale University |
Junction-fragment DNA probes and probe clusters
|
SU1364343A1
(ru)
*
|
1984-07-13 |
1988-01-07 |
Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов |
Способ получени человеческого лейкоцитарного интерферона альфа-2
|
US5871956A
(en)
*
|
1984-12-06 |
1999-02-16 |
Amgen Inc. |
Recombinant methods for production of serine inhibitors and DNA sequences useful for same
|
US6291662B1
(en)
|
1984-12-05 |
2001-09-18 |
Amgen Inc. |
Recombinant methods for production of serine protease inhibitors and DNA sequences
|
US6132990A
(en)
*
|
1984-12-06 |
2000-10-17 |
Amgen Boulder Inc. |
Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
|
US5900400A
(en)
*
|
1984-12-06 |
1999-05-04 |
Amgen Inc. |
Serine protease inhibitor analogs
|
US4879224A
(en)
*
|
1985-01-10 |
1989-11-07 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
|
US4950646A
(en)
*
|
1985-01-10 |
1990-08-21 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing human lipocortin-like polypeptides
|
US4874743A
(en)
*
|
1985-01-10 |
1989-10-17 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor-like polypeptides
|
US5081019A
(en)
*
|
1985-01-10 |
1992-01-14 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides
|
DE3688383T2
(de)
|
1985-02-05 |
1993-08-26 |
Synergen Biolog Inc |
Rekombinantes vektorsystem fuer metalloproteinase-inhibitorsequenz und dessen verwendung und herstellung nach dem rekombinant-dns-verfahren.
|
JPS61185189A
(ja)
*
|
1985-02-08 |
1986-08-18 |
Green Cross Corp:The |
新規インタ−フエロン−α↓1DNA配列、組み換えプラスミド及び形質転換体
|
US4894332A
(en)
*
|
1985-03-27 |
1990-01-16 |
Biogen, Inc. |
DNA sequences coding for Mycoplasma hypopneumoniae surface antigens, methods of use to make the corresponding proteins
|
US4956282A
(en)
*
|
1985-07-29 |
1990-09-11 |
Calgene, Inc. |
Mammalian peptide expression in plant cells
|
US6774283B1
(en)
|
1985-07-29 |
2004-08-10 |
Calgene Llc |
Molecular farming
|
US5248603A
(en)
*
|
1985-09-03 |
1993-09-28 |
Symbicom Aktiebolag |
Superoxide dismutase
|
DK402785D0
(da)
*
|
1985-09-03 |
1985-09-03 |
Syn Tek Ab |
Fremgangsmaade til fremstilling af et enzym
|
US5135868A
(en)
*
|
1985-10-25 |
1992-08-04 |
Phillips Petroleum Company |
Cultures of yeast of the genus Pichia altered by site selective genomic modification
|
US4882279A
(en)
*
|
1985-10-25 |
1989-11-21 |
Phillips Petroleum Company |
Site selective genomic modification of yeast of the genus pichia
|
US5028422A
(en)
*
|
1986-05-27 |
1991-07-02 |
Schering Corporation |
Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
|
US5089406A
(en)
*
|
1987-01-07 |
1992-02-18 |
Allied-Signal Inc. |
Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences
|
AU623589B2
(en)
*
|
1987-03-02 |
1992-05-21 |
Bristol-Myers Squibb Company |
Platelet related growth regulator
|
JPS6463395A
(en)
|
1987-05-04 |
1989-03-09 |
Oncogen |
Oncostatin m and novel composition having antitumor activity
|
US4961969A
(en)
*
|
1987-05-11 |
1990-10-09 |
Cetus Corporation |
Process for recovering microbially produced interferon-β
|
US5714585A
(en)
*
|
1987-10-26 |
1998-02-03 |
Sterling Winthrop, Inc. |
Antibodies that are immunoreactive with interleukin-7
|
US5328988A
(en)
*
|
1987-10-26 |
1994-07-12 |
Immunex Corporation |
Interleukin-7
|
ATE124087T1
(de)
*
|
1988-02-26 |
1995-07-15 |
Biogen Inc |
Dna-sequenzen, rekombinante dna-moleküle und verfahren zur herstellung von lipocortin iii, iv, v, und vi.
|
US5605815A
(en)
*
|
1988-03-14 |
1997-02-25 |
Yale University |
Nucleic acids encoding and expression of parathyroid hormone-like peptide
|
EP0409901A4
(en)
*
|
1988-04-15 |
1991-10-30 |
Research Corporation Technologies, Inc |
Lak cell cytotoxin
|
DK455789D0
(da)
*
|
1989-09-15 |
1989-09-15 |
Symbicom Ab |
Polypeptid
|
JP2772062B2
(ja)
*
|
1989-09-26 |
1998-07-02 |
株式会社ニッコー |
走行玩具の方向変換装置
|
US5256568A
(en)
*
|
1990-02-12 |
1993-10-26 |
Regeneron Phamaceuticals, Inc. |
Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
|
HUT65827A
(en)
*
|
1990-04-02 |
1994-07-28 |
Synergen Inc |
Polypeptides useful in animal treatment against mycoplasma infections
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5676942A
(en)
*
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
CA2129533A1
(en)
*
|
1992-02-10 |
1993-08-19 |
Douglas Testa |
Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
|
US5912015A
(en)
*
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
US5711968A
(en)
|
1994-07-25 |
1998-01-27 |
Alkermes Controlled Therapeutics, Inc. |
Composition and method for the controlled release of metal cation-stabilized interferon
|
US6869925B1
(en)
*
|
1992-09-09 |
2005-03-22 |
Amgen Inc. |
Inhibition of retrovirus infection
|
JP2649317B2
(ja)
*
|
1993-10-25 |
1997-09-03 |
株式会社キジマ |
手袋の製造方法
|
US6017880A
(en)
*
|
1994-03-09 |
2000-01-25 |
Amgen Inc. |
Inhibition of retrovirus infection
|
KR20060099543A
(ko)
*
|
1994-12-09 |
2006-09-19 |
임페리얼 컬리지 이노베이션스 리미티드 |
유전자의 동정
|
US6387365B1
(en)
|
1995-05-19 |
2002-05-14 |
Schering Corporation |
Combination therapy for chronic hepatitis C infection
|
CA2230494A1
(en)
*
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics Inc. |
Composition for sustained release of an agent
|
EP0858343B1
(en)
|
1995-11-02 |
2004-03-31 |
Schering Corporation |
Continuous low-dose cytokine infusion therapy
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
US6027721A
(en)
*
|
1996-05-20 |
2000-02-22 |
Cytotherapeutics, Inc. |
Device and method for encapsulated gene therapy
|
GB9712370D0
(en)
*
|
1997-06-14 |
1997-08-13 |
Aepact Ltd |
Therapeutic systems
|
US6172046B1
(en)
|
1997-09-21 |
2001-01-09 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
|
US6472373B1
(en)
|
1997-09-21 |
2002-10-29 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
JP2001523480A
(ja)
|
1997-11-20 |
2001-11-27 |
バイカル インコーポレイテッド |
サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
|
KR100694345B1
(ko)
|
1998-05-15 |
2007-03-12 |
쉐링 코포레이션 |
리바비린 및 인터페론 알파를 포함하는, 만성 c형 간염에 걸린 항-바이러스 치료에 대한 나이브 환자의 치료용 약제학적 조성물
|
CA2341349C
(en)
*
|
1998-09-04 |
2013-12-10 |
Creatogen Aktiengesellschaft |
Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof
|
JP4468585B2
(ja)
|
1998-11-12 |
2010-05-26 |
シェーリング コーポレイション |
インターフェロンアイソフォームおよびその産物の変換の方法
|
US6281337B1
(en)
|
1998-11-12 |
2001-08-28 |
Schering Corporation |
Methods for conversion of protein isoforms
|
CN1390132A
(zh)
|
1999-04-08 |
2003-01-08 |
先灵公司 |
聚乙二醇化干扰素α在黑素瘤治疗中的应用
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
US6923966B2
(en)
*
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
GB9910812D0
(en)
*
|
1999-05-10 |
1999-07-07 |
Microscience Ltd |
Vaccine composition
|
GB0008419D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Bioinvent Int Ab |
A method for invitro molecular evolution of antibody function
|
AU2001266557A1
(en)
|
2000-04-12 |
2001-10-23 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
GB0008966D0
(en)
*
|
2000-04-13 |
2000-05-31 |
Imp College Innovations Ltd |
Vectors for gene therapy
|
JP2006510567A
(ja)
*
|
2001-02-20 |
2006-03-30 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
腫瘍の治療のための細胞治療方法
|
US20040071671A1
(en)
*
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
JP4660067B2
(ja)
|
2001-04-24 |
2011-03-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗血管新生剤とTNFαとを用いる組合せ療法
|
KR101271635B1
(ko)
*
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
US20080194481A1
(en)
*
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
GB0217033D0
(en)
|
2002-07-23 |
2002-08-28 |
Delta Biotechnology Ltd |
Gene and polypeptide sequences
|
GB0226105D0
(en)
*
|
2002-11-08 |
2002-12-18 |
St Georges S Entpr Ltd |
Pain relief agents
|
GB0304993D0
(en)
*
|
2003-03-05 |
2003-04-09 |
Univ Nottingham Trent |
Novel screening method
|
KR20060116825A
(ko)
|
2003-10-23 |
2006-11-15 |
일루미겐 바이오사이언시스, 인코포레이티드 |
바이러스 감염에 대한 저항성과 관련된 유전자인oas1에서의 돌연변이의 검출
|
CA2552590A1
(en)
*
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
WO2005074650A2
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human four helical bundle polypeptides and their uses
|
GB0420091D0
(en)
*
|
2004-09-10 |
2004-10-13 |
Univ Nottingham Trent |
Medical implant materials
|
US20060193849A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Antisoma Plc |
Biological materials and uses thereof
|
GB0514661D0
(en)
*
|
2005-07-16 |
2005-08-24 |
Medical Res Council |
Methods
|
PT1806358E
(pt)
|
2005-09-05 |
2010-05-28 |
Immatics Biotechnologies Gmbh |
Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
|
ATE440107T1
(de)
|
2005-09-05 |
2009-09-15 |
Immatics Biotechnologies Gmbh |
Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
GB0519398D0
(en)
*
|
2005-09-23 |
2005-11-02 |
Antisoma Plc |
Biological materials and uses thereof
|
GB0607354D0
(en)
|
2006-04-12 |
2006-05-24 |
Bioinvent Int Ab |
Agent, Composition And Method
|
GB0607798D0
(en)
*
|
2006-04-20 |
2006-05-31 |
Alligator Bioscience Ab |
Novel polypeptides and use thereof
|
CN101657720A
(zh)
*
|
2006-05-31 |
2010-02-24 |
荷兰联合利华有限公司 |
筛选改变皮肤和/或头发色素沉着的化合物的方法
|
EP2474318A1
(en)
*
|
2006-06-07 |
2012-07-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
PT2660248E
(pt)
|
2007-07-27 |
2015-10-12 |
Immatics Biotechnologies Gmbh |
Nova imunoterapia para tumores neuronais e cerebrais
|
CA2694805C
(en)
|
2007-07-27 |
2014-09-09 |
Immatics Biotechnologies Gmbh |
Immunogenic epitopes of tumour-associated antigens
|
WO2009028573A1
(ja)
|
2007-08-27 |
2009-03-05 |
National University Corporation Nagoya University |
血液凝固障害におけるリバビリンの利用
|
CN101998965B
(zh)
|
2007-11-01 |
2014-03-12 |
安斯泰来制药有限公司 |
免疫抑制性多肽与核酸
|
WO2009068436A1
(en)
*
|
2007-11-27 |
2009-06-04 |
Unilever Plc |
Screening methods
|
ES2554981T3
(es)
|
2008-03-27 |
2015-12-28 |
Immatics Biotechnologies Gmbh |
Nueva inmunoterapia contra tumores neuronales y cerebrales
|
NO2119726T3
(ro)
|
2008-05-14 |
2015-05-23 |
|
|
US8703153B2
(en)
|
2008-06-16 |
2014-04-22 |
Prokarium Ltd. |
Salmonella vectored vaccines against Chlamydia and methods of use
|
PT2172211E
(pt)
|
2008-10-01 |
2015-03-09 |
Immatics Biotechnologies Gmbh |
Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
|
JP2012504653A
(ja)
*
|
2008-10-03 |
2012-02-23 |
ザ・シャーロット‐メクレンバーグ・ホスピタル・オーソリティ,ドゥーイング・ビジネス・アズ・キャロライナズ・メディカル・センター |
金属ポルフィリンによるc型肝炎感染症の治療
|
ES2342529B1
(es)
|
2008-10-07 |
2011-05-11 |
Proyecto De Biomedicina Cima, S.L. |
Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
|
JP2012513200A
(ja)
|
2008-12-23 |
2012-06-14 |
シェーリング コーポレイション |
組換え製造インターフェロンの精製
|
GB0905790D0
(en)
|
2009-04-03 |
2009-05-20 |
Alligator Bioscience Ab |
Novel polypeptides and use thereof
|
US8993808B2
(en)
|
2009-01-21 |
2015-03-31 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8623348B2
(en)
|
2009-03-27 |
2014-01-07 |
Jw Pharmaceutical Corporation |
Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
|
EP2459191A1
(en)
|
2009-07-31 |
2012-06-06 |
OSI Pharmaceuticals, LLC |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
MX338041B
(es)
|
2009-09-25 |
2016-03-30 |
Oryzon Genomics Sa |
Inhibidores de demetilasa-1 especificos de lisina y su uso.
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
WO2011046221A1
(ja)
*
|
2009-10-16 |
2011-04-21 |
学校法人立命館 |
インターフェロン-αモジュレーター
|
EA201200650A1
(ru)
|
2009-10-30 |
2012-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
|
DK2513146T3
(en)
|
2009-12-18 |
2017-07-31 |
Kancera Ab |
Antibodies against ROR1 capable of inducing cell death by CLL
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
CA2783656A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
GB201019331D0
(en)
|
2010-03-19 |
2010-12-29 |
Immatics Biotechnologies Gmbh |
Methods for the diagnosis and treatment of cancer based on AVL9
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
ES2607081T3
(es)
|
2010-04-19 |
2017-03-29 |
Oryzon Genomics, S.A. |
Inhibidores de desmetilasa específica de lisina-1 y su uso
|
WO2011161644A1
(en)
|
2010-06-24 |
2011-12-29 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
EP2598480B1
(en)
|
2010-07-29 |
2019-04-24 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
LT2598482T
(lt)
|
2010-07-29 |
2018-07-10 |
Oryzon Genomics, S.A. |
Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
|
WO2012045883A1
(en)
|
2010-10-08 |
2012-04-12 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
WO2012107499A1
(en)
|
2011-02-08 |
2012-08-16 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
|
WO2012107498A1
(en)
|
2011-02-08 |
2012-08-16 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
GB2490655A
(en)
|
2011-04-28 |
2012-11-14 |
Univ Aston |
Modulators of tissue transglutaminase
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
CA2849564C
(en)
|
2011-10-20 |
2020-10-20 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
BR112014009306B1
(pt)
|
2011-10-20 |
2021-07-20 |
Oryzon Genomics S.A. |
Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1
|
CA2853495A1
(en)
|
2011-10-31 |
2013-05-10 |
Gilead Pharmasset Llc |
Methods and compositions for treating hepatitis c virus
|
BR112014012739A8
(pt)
|
2011-11-29 |
2017-06-20 |
Gilead Pharmasset Llc |
composições e métodos para o tratamento do vírus da hepatite c
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
GB201219678D0
(en)
|
2012-11-01 |
2012-12-12 |
Benf Ab |
Ketone body inhibitors and uses thereof
|
DK2961766T3
(da)
|
2013-03-01 |
2019-07-15 |
Boehringer Ingelheim Animal Health Usa Inc |
Kvantificering af vaccinesammensætninger
|
US20140357595A1
(en)
|
2013-06-04 |
2014-12-04 |
Gilead Pharmasset Llc |
Methods of preventing and treating recurrence of a hepatitis c virus infection in a subject after the subject has received a liver transplant
|
TWI777194B
(zh)
|
2013-08-05 |
2022-09-11 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(一)
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
ES2896404T3
(es)
|
2014-04-04 |
2022-02-24 |
Crown Bioscience Inc Taicang |
Métodos para determinar la capacidad de respuesta a inhibidores de MEK/ERK
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
IL308735A
(en)
|
2015-07-01 |
2024-01-01 |
Immatics Biotechnologies Gmbh |
New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
|
EP4321172A2
(en)
|
2015-07-06 |
2024-02-14 |
immatics biotechnologies GmbH |
Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
MX2018006781A
(es)
|
2015-12-03 |
2018-11-09 |
Agios Pharmaceuticals Inc |
Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
CN116375797A
(zh)
|
2016-03-01 |
2023-07-04 |
伊玛提克斯生物技术有限公司 |
用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
|
PT3430037T
(pt)
|
2016-03-16 |
2022-11-23 |
Immatics Biotechnologies Gmbh |
Células t transfetadas e recetores de células t para uso em imunoterapia anticancro
|
EP4357454A2
(en)
|
2016-03-16 |
2024-04-24 |
Immatics Biotechnologies GmbH |
Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
|
MY197258A
(en)
|
2016-04-06 |
2023-06-08 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
|
TW202304970A
(zh)
|
2016-08-26 |
2023-02-01 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
MA47367B1
(fr)
|
2017-01-27 |
2023-06-28 |
Immatics Biotechnologies Gmbh |
Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
|
US11427614B2
(en)
|
2017-04-10 |
2022-08-30 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
MA49122A
(fr)
|
2017-04-10 |
2021-03-24 |
Immatics Biotechnologies Gmbh |
Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
|
EA201992416A1
(ru)
|
2017-04-10 |
2020-02-25 |
Имматикс Байотекнолоджиз Гмбх |
Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
|
TW201906859A
(zh)
|
2017-07-07 |
2019-02-16 |
德商英麥提克生物技術股份有限公司 |
用於肺癌(包括 nsclc、sclc 和其他癌症)免疫治療的新型肽和肽組合物
|
WO2019007974A1
(en)
|
2017-07-07 |
2019-01-10 |
Immatics Biotechnologies Gmbh |
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|